PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 19, 2024Proceedings of the National Academy of Sciences50 citationsOpen Access

The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity

View Full Paper
JFJeffrey M. Friedman

Key Points

  • Discovery of the active hormone GLP-1(7-37) and subsequent molecular engineering enabled the creation of effective therapeutic agents for weight reduction.
  • The 2024 Lasker~DeBakey Clinical Medical Research Award recognized pioneering advances in peptide chemistry and molecular biology that solved a century-old mystery.
  • Historical narrative details how multidisciplinary collaboration across endocrinology and pharmacology led to sustained-acting GLP-1 treatments for global obesity.

Abstract

The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity. Each of the three had a distinct set of skills that made this advance possible; Habener is an endocrinologist and molecular biologist, Mojsov is a peptide chemist, and Knudsen is a pharmaceutical scientist. Their collective efforts have done what few thought possible-the development of highly effective medicines for reducing weight. Their research has also solved a mystery that began more than a century ago.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jeffrey M. Friedman (2024) studied this question.

synapsesocial.com/papers/68e57fadb6db64358751d18bhttps://doi.org/10.1073/pnas.2415550121
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids1968 · 200 citations
  2. 2Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects1992 · 291 citations
  3. 3Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes2015 · 1,165 citations
  4. 4Exendin peptides.1992 · 11 citations
  5. 5Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem.1982 · 288 citations